Venture Life Group plc Stock

Equities

VLG

GB00BFPM8908

Pharmaceuticals

Delayed London S.E. 06:28:16 2024-04-23 am EDT 5-day change 1st Jan Change
39.9 GBX +3.64% Intraday chart for Venture Life Group plc +4.31% +19.10%
Sales 2023 51.41M 63.75M Sales 2024 * 55.02M 68.22M Capitalization 48.7M 60.39M
Net income 2023 - 0 Net income 2024 * 2M 2.48M EV / Sales 2023 0.82 x
Net Debt 2023 * 10.47M 12.98M Net Debt 2024 * 9.17M 11.37M EV / Sales 2024 * 1.05 x
P/E ratio 2023
49.3 x
P/E ratio 2024 *
20.9 x
Employees 153
Yield 2023 *
-
Yield 2024 *
-
Free-Float 83.5%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.64%
1 week+4.31%
Current month+8.57%
1 month+7.84%
3 months+15.65%
6 months+45.09%
Current year+19.10%
More quotes
1 week
36.80
Extreme 36.8
40.00
1 month
35.50
Extreme 35.5
40.00
Current year
32.30
Extreme 32.3
41.90
1 year
27.00
Extreme 27
43.50
3 years
23.00
Extreme 23
105.00
5 years
20.00
Extreme 20
118.00
10 years
20.00
Extreme 20
118.00
More quotes
Managers TitleAgeSince
Founder 60 05-12-11
Director of Finance/CFO 37 21-11-30
Director/Board Member - 14-03-23
Members of the board TitleAgeSince
Founder 60 05-12-11
Director/Board Member 60 22-10-09
Director/Board Member - 14-03-23
More insiders
Date Price Change Volume
24-04-23 39.9 +3.64% 37 697
24-04-22 38.5 -1.28% 55,278
24-04-19 39 +1.96% 299,065
24-04-18 38.25 -1.42% 11,045
24-04-17 38.8 +1.44% 69,400

Delayed Quote London S.E., April 23, 2024 at 06:28 am EDT

More quotes
Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.385 GBP
Average target price
0.76 GBP
Spread / Average Target
+97.40%
Consensus

Annual profits - Rate of surprise